BioNTech, Autolus strike wide-ranging licensing and manufacturing deal for CAR-T therapies
2024-02-08
引进/卖出细胞疗法免疫疗法临床研究
BioNTech is enlisting CAR-T biotech Autolus Therapeutics on a partnership aimed at pushing both of their CAR-T programs toward commercialization, with an eye on its new partner’s programs as well as manufacturing capabilities.
As part of the wide-ranging agreement, BioNTech will purchase $200 million of Autolus’ shares in a private placement, plus dish out a cash payment of $50 million.
In exchange, BioNTech will receive up to mid-single digit royalty on net sales of Autolus’ lead CD19 therapy, obe-cel, which is now under review at the FDA for relapsed/refractory adult B cell acute lymphoblastic leukemia. It will also have an option to get a profit share on Autolus’ other CAR-T therapies, AUTO1/22 and AUTO6NG, in any cancer type, if it co-supports development and commercialization. Autolus will be eligible to receive an option exercise fee, milestone payments and co-funding of development expenses.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。